The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.
Biological: Human Amniotic Fluid
Administration of amniotic fluid in SARS-CoV-2 positive patients
Inclusion Criteria:
- 1. Age ≥18
- 2. Hospitalized and symptomatic (cough, fevers, SOB, or sputum production)
- 3. SARS CoV-2 laboratory positive obtained within 14 days of enrollment
Exclusion Criteria:
- 1. None
University of Utah Health
Salt Lake City, Utah, United States
Craig Selzman, MD, Principal Investigator
University of Utah